Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kelly G Sprankle

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Coronary Artery Disease|July 19, 2013
Bioresorbable polystatin fourth-generation stentsWayne H Kaesemeyer, Kelly G Sprankle, Jon N Kremsky, et al.
Journal of Medicinal Chemistry|December 12, 2003
Structure-based design, synthesis, and antimicrobial activity of indazole-derived SAH/MTA nucleosidase inhibitorsXiaoming Li, Sam Chu, Victoria A Feher, et al.
Journal of Medicinal Chemistry|September 17, 2009
Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitorQi Chao, Kelly G Sprankle, Robert M Grotzfeld, et al.
Blood|August 6, 2009
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)Patrick P Zarrinkar, Ruwanthi N Gunawardane, Merryl D Cramer, et al.
Bioorganic & Medicinal Chemistry Letters|August 4, 2009
Arylcarboxyamino-substituted diaryl ureas as potent and selective FLT3 inhibitorsHitesh K Patel, Robert M Grotzfeld, Andiliy G Lai, et al.
Bioorganic & Medicinal Chemistry Letters|August 3, 2011
4-Quinazolinyloxy-diaryl ureas as novel BRAFV600E inhibitorsMark W Holladay, Brian T Campbell, Martin W Rowbottom, et al.
Journal of Medicinal Chemistry|December 16, 2011
Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600EMartin W Rowbottom, Raffaella Faraoni, Qi Chao, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Coronary Artery Disease|July 19, 2013
Bioresorbable polystatin fourth-generation stentsWayne H Kaesemeyer, Kelly G Sprankle, Jon N Kremsky, et al.
Journal of Medicinal Chemistry|December 12, 2003
Structure-based design, synthesis, and antimicrobial activity of indazole-derived SAH/MTA nucleosidase inhibitorsXiaoming Li, Sam Chu, Victoria A Feher, et al.
Journal of Medicinal Chemistry|September 17, 2009
Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitorQi Chao, Kelly G Sprankle, Robert M Grotzfeld, et al.
Blood|August 6, 2009
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)Patrick P Zarrinkar, Ruwanthi N Gunawardane, Merryl D Cramer, et al.
Bioorganic & Medicinal Chemistry Letters|August 4, 2009
Arylcarboxyamino-substituted diaryl ureas as potent and selective FLT3 inhibitorsHitesh K Patel, Robert M Grotzfeld, Andiliy G Lai, et al.
Bioorganic & Medicinal Chemistry Letters|August 3, 2011
4-Quinazolinyloxy-diaryl ureas as novel BRAFV600E inhibitorsMark W Holladay, Brian T Campbell, Martin W Rowbottom, et al.
Journal of Medicinal Chemistry|December 16, 2011
Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600EMartin W Rowbottom, Raffaella Faraoni, Qi Chao, et al.
Pageof 1